Tactiva Therapeutics Reports Data Highlighting a Novel Dual CD4/CD8 T Cell Receptor with Potential for Use Against a Broad Range of Cancers
Tactiva Therapeutics today reported on its unique, dual enhanced adoptive cell therapy (DEACT) platform, incorporating its proprietary, engineered CD4/CD8 T cell receptors (TCR) with potential broad utility in cancer immunotherapy, including melanoma and ovarian cancer. A late breaking abstract describing these findings was presented as part of the Annual Meeting of the American Association of Cancer Research (AACR), [PR.com]
More From Around the Web
Check out these Articles
- Shire clinches $32bn takeover of Baxalta
- AstraZeneca boasts of strong drug pipeline as Pfizer deadline looms
- 2015-2016 Report of the Committee on Law Enforcement/Legislation
- Novartis Explore Novel Approaches to Disease Modelling and Organoid Technol...
- Two States Propose Regulations Related to Telemedicine Practice
- MHRA Exclusive: Spotlight on Effective Biobanking Operations and Regulatory...
- Pharmacy Technician Certification Board To Introduce Updated Certification ...
- UK pharma firms accused of illegal deals to hike price of life-saving drug
- Multiple sclerosis patients may benefit from statins, says study
- Platelet Rich Plasma (PRP) Market Size, Share, Growth, Trends and Forecast ...
- Highly paid bosses should not get knighthoods, City veteran tells MPs
- OnkoDataMed Joins ACM, ICRC-Weyer in Medis Research Group
- Trial Runners LLC is a “Great Place To Work®”
- Pfizer seeks to quell UK research fears over proposed takeover of AstraZene...
- Regenerative Medicine Market to Reach $30,237 Million, Globally by 2022
- July DEA Conference on Preventing Drug Diversion Open to Pharmacy Personnel...
- AstraZeneca is free of Pfizer for now